EC
LRMR icon

EntryPoint Capital’s Larimar Therapeutics LRMR Stock Holding History

EntryPoint Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,479
Closed -$200K – 885
2026
Q1 		$200K Sell
44,479
-8,842
-17% -$35.3K 0.06% 647
2025
Q4 		$203K Buy
+53,321
New +$207K 0.08% 548
2025
Q1 		– Sell
-54,281
Closed -$210K – 837
2024
Q4 		$210K Buy
54,281
+36,045
+198% +$238K 0.09% 576
2024
Q3 		$119K Buy
18,236
+4,145
+29% +$33.3K 0.07% 544
2024
Q2 		$102K Buy
14,091
+164
+1% +$1.26K 0.05% 808
2024
Q1 		$106K Buy
+13,927
New +$109K 0.09% 392

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

EntryPoint Capital's LRMR Position: Q2 2026 in Review

EntryPoint Capital sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 44,479 shares — an estimated $200K sold.

EntryPoint Capital first reported a position in LRMR in Q1 2024 and held it in 6 quarters. The position peaked at $210K in Q4 2024. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • EntryPoint Capital reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 44,479 Larimar Therapeutics shares in Q2 2026, an estimated $200K.
  • EntryPoint Capital first reported a position in Larimar Therapeutics in Q1 2024 and held it in 6 quarters.
  • EntryPoint Capital's Larimar Therapeutics position peaked at $210K in Q4 2024.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.